Trump’s Food and Drug Administration has been compelled by the United Nations World Health Organization (WHO) to ask the American public a very timely question – should marijuana be reclassified under Article 2 of the 1971 Convention on Psychotropic Substances?
WHO will convene in a special session in Geneva, Switzerland, June 4 – 8 to review the following substances:
- Cannabis plant and cannabis resin
- Extracts and tinctures of cannabis
- Delta-9-tetrahydrocannabinol (THC)
- Isomers of THC
A simple ask of the American public, the requested comments seek input on potentially reclassifying the cannabis plant and its therapeutic compounds on a global scale.
Per the Federal Register, the FDA is asking individuals submit their comments regarding potential abuse, actual abuse, medicinal efficacy, drug trafficking, and the potential impact of rescheduling marijuana for medicinal purposes.
The WHO questionnaire asks individuals about their therapeutic use of the cannabis plant’s resin, extracts, tinctures, THC, and CBD oil – and whether or not the products were “approved” for “therapeutic” use in their country of origin. The World Health Organization’s survey was specifically designed to collectively gather relevant information on the plant’s legitimate use, harmful use, and legal status.
Paragraph (d)(2)(A) of the CSA (21 U.S.C. 811) (Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970) provides that when WHO notifies the United States under Article 2 of the Psychotropic Convention that it has information that may justify adding a drug or other substances to one of the schedules of the Psychotropic Convention, transferring a drug or substance from one schedule to another, or deleting it from the schedules, the Secretary of State must transmit the notice to the Secretary of Health and Human Services (Secretary of HHS). The Secretary of HHS must then publish the notice in the Federal Register and provide opportunity for interested persons to submit comments that will be considered by HHS in its preparation of the scientific and medical evaluations of the drug or substance.”
In a November 2017 pre-review report on cannabidiol, WHO concluded the cannabis plant’s non-psychoactive CBD cannabinoid may have therapeutic benefits for those suffering from Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington’s disease, psychosis, anxiety, depression, cancer, nausea, inflammatory diseases, rheumatoid arthritis, IBS/ Crohn’s disease, cardiovascular disease and diabetic complications.